AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05005377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket Preservation with Platelet-Rich Fibrin
Description: 10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
Study NCT05005377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket Preservation with Freeze-Dried Bone Allograft
Description: The extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus
Description: 0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP IPV//Hib vaccine
Description: 0.5 mL, intramuscular
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL, subcutaneous
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 0.5 mL, subcutaneous
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Description: 0.5 mL, intramuscular
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus
Description: 0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
Study NCT01411241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL, subcutaneously
Study NCT05147870 — intervention group
Intervention type: PROCEDURE
Intervention: Peritoneal irrigation
Description: For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
Study NCT05147870 — intervention group
Intervention type: PROCEDURE
Intervention: Suction only
Description: In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
Study NCT01798875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral metformin
Study NCT01798875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive
Study NCT00769600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Itraconazole 200 mg once daily
Study NCT00769600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed every 21 days.
Study NCT00551330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc 30 mg once daily
Study NCT02599064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Description: RXI-109 dosed intravitreally to subjects with NVAMD
Study NCT05702099 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: By performing transvaginal or transabdominal ultrasonography on women, ovarian volume will be calculated and antral follicle will be counted.
Study NCT04229771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic
Study NCT04229771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Description: One drop instilled in one eye, randomly chosen, as control placebo
Study NCT00962078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: continuous endurance training
Description: at 60 percent of peak Watt
Study NCT00962078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interval training
Description: at 100 percent of peak Watt
Study NCT00551330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo once daily
Study NCT03205670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urethroplasty with a tissue-engineered construct
Description: The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
Study NCT01653938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Study NCT00833872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 22811
Description: First-in-man
Study NCT00833872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Study NCT02749097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0534
Study NCT02749097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04047277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
Study NCT03473353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Scribe
Description: Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
Study NCT03818126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: del Nido cardioplegia
Description: The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit.
Study NCT03818126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cold blood cardioplegia
Description: The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius.
Study NCT02398253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + Hypo-energetic Diet
Description: This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
Study NCT02398253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypo-energetic Diet only
Description: This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
Study NCT02833805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
Study NCT02833805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6 through -2: 30 mg/m\^2 IV daily
Study NCT02833805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
Study NCT02833805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 centigray (cGy) in a single fraction
Study NCT02833805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day 5 through Day 365
Study NCT02833805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
Study NCT02530710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q203
Study NCT02530710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02989623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Given Intravenously
Study NCT02989623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo copper Cu 64 TP3805 PET/CT scan
Study NCT02975063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A&T IYCF intervention
Description: (1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
Study NCT01597843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
Study NCT02015988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Study NCT02015988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT02015988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT03082937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg [14C]-A4250 capsule
Description: Each subject will receive a single administration of 3 mg \[14C\]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.
Study NCT05567107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Classical foot massage was applied by the researcher with efflorescence, superficial friction and petrissage techniques for 10 minutes on each foot.
Study NCT02562820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: Intravenous infusion of Ketamine
Study NCT02562820 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion
Description: Intravenous infusion of Normal Saline
Study NCT01907906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol System for Whole Blood
Description: LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
Study NCT03907267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine Solution
Description: Taurine Solution
Study NCT03907267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline
Study NCT01634269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2111 TAVI 23 mm
Description: Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
Study NCT02431052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil
Study NCT02431052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT04301570 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound device
Description: The measurement of bone age is performed via ultrasound with the Ultrasound System for Bone Age Assessment (BAUS) from Sonic Bone (SonicBone Medical Ltd., Rishon Lezion, Israel).
Study NCT04301570 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: XR
Description: The measurement of bone age is performed via imaging procedure via X-ray (Röntgengerät, Stadler SE 4600, Littau, CH) of the left hand.
Study NCT04144647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single testing session
Description: All participants that meet the inclusion criteria, will have to attend the research laboratory at Centre for Human and Applied Physiological Sciences, Shepherd's House, Guy's Campus, King's College London, SE1 1UL to be assessed in a single testing session.~The testing session will require them to complete some questionnaires regarding balance confidence, psychological state, sleep and physical function and to undertake some simple tests of cognitive function. They will also undertake a brief dynamic balance assessment and the dual-task gait test. The dual-task component involves two cognitive tasks (a numeracy and a literacy task) or auditory task. The gait test will be performed separately and then together with each of two cognitive tasks or auditory task.~On the day, after the testing, each participant will, also, be provided a physical activity monitor (accelerometer-AX3) to wear on their wrist for 24 hours a day, seven days a week without taking it off.
Study NCT04273139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBRUTINIB
Description: Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
Study NCT04273139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
Study NCT04540445 — intervention group
Intervention type: OTHER
Intervention: Pupillary Assessment
Description: Pupillary assessment with handheld pupillometer
Study NCT01482936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone (OxyNorm®) Injection
Description: The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
Study NCT01819142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoloGel
Description: AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
Study NCT01139788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624587
Description: 6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).
Study NCT05772143 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous discectomies under CT
Description: Percutaneous discectomies under CT guidance to treat lumbar disc herniations resistant to conservative treatment and nerve root infiltrations.
Study NCT00540033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: infloran
Description: Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
Study NCT00540033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: infloran
Description: Study group was fed with infloran \[Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)\] and Bifidobacteria bifidum \[(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)\]; Laboratorio Farmaceutico S.I.T S.r.I ITALY\] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
Study NCT00639327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 + irinotecan
Description: Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
Study NCT00639327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Irinotecan 150mg/m2 iv on day one every two weeks until PD
Study NCT04199286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: symmetrical and asymmetrical horizontal strabismus surgery
Description: surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
Study NCT01168947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% dextrose solution
Description: The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
Study NCT01857804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
Study NCT01857804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
Study NCT01857804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
Study NCT01971515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2363318A
Description: Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).
Study NCT01971515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2363318A plus Trastuzumab
Description: Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion.
Study NCT01971515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2363318A plus Tamoxifen
Description: Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration.
Study NCT03142776 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: periodontal debridement
Study NCT03142776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal debridement
Study NCT03142776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photodynamic therapy
Study NCT03142776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic clarithromycin